Various IL-17 inhibitors, such as secukinumab, ixekizumab, bimekizumab, and brodalumab, have been explored for their potential to treat psoriasis by blocking IL-17-mediated NF-κB activation, demonstrating encouraging results in alleviating cutaneous inflammation [160]. Here, IL17A is linked to psoriasis.